Company:  EVOFEM BIOSCIENCES, INC. (EVFM)
Form Type:  S-3
Filing Date:  7/30/2021 
CIK:  0001618835 
Address:  12400 HIGH BLUFF DRIVE
SUITE 600
 
City, State, Zip:  SAN DIEGO, California 92130 
Telephone:  (858) 550-1900 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.71  
Change: 
0.0131 (1.89%)  
Trade Time: 
Oct 18  
Market Cap: 
$121.34M
Trade EVFM now with 

© 2021  
Description of Business
We are a San Diego-based commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Our first commercial product, Phexxi vaginal gel, was approved by the FDA on May 22, 2020 and commercially launched in the United States in September 2020. Phexxi is the first and only FDA-approved hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Our strategy is to commercialize Phexxi in the United States ourselves and in all other global markets through partnerships. Our lead product candidate EVO100 is being evaluated in women for the prevention of chlamydia and gonorrhea - two of the most pervasive sexually transmitted infections (STIs) in the United States. Currently, there are no FDA-approved prescription products to prevent infection by either of these common and dangerous pathogens.
Register and access this filing in:     
  FORM S-3
    CALCULATION OF REGISTRATION FEE
    SUBJECT TO COMPLETION, DATED JULY 30, 2021
    TABLE OF CONTENTS
    PROSPECTUS SUMMARY
    RISK FACTORS
    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    PLAN OF DISTRIBUTION
    DESCRIPTION OF CAPITAL STOCK
    DESCRIPTION OF DEBT SECURITIES
    DESCRIPTION OF WARRANTS
    Transfer Agent and Registrar
    DESCRIPTION OF UNITS
    LEGAL MATTERS
    EXPERTS
    WHERE YOU CAN FIND MORE INFORMATION
      INCORPORATION OF DOCUMENTS BY REFERENCE
    PART II
      Item 14. Other Expenses of Issuance and Distribution
      Item 15. Indemnification of Directors and Officers
      Item 16. Exhibits
      Item 17. Undertakings
    EXHIBIT INDEX
    SIGNATURES
    SIGNATURES AND POWER OF ATTORNEY
  EXHIBIT 4.4
  EXHIBIT 4.5
  EXHIBIT 5.1
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM